Overview of Research Registries |
| Author: Shelley Ensz. Scleroderma is highly variable. See Types of Scleroderma. Read Disclaimer |
|
|
Overview of Research Registries |
Join as many research registries as you possibly can! |
| You may join all of the research registries and quality of life studies that you are eligible for. It's not like clinical trials, where you are limited to just one. |
Registries for Rheumatic Diseases |
| The National Data Bank (NDB) for rheumatic diseases: Diagnosis List. If you have been diagnosed with one or more conditions from the following list, you are eligible to participate in NDB research. If you have a diagnosis for a rheumatic disease that you do not see listed, please contact us. The NDB for Rheumatic Disease, 2011. (Also see: Rheumatic Diseases) |
Scleroderma Experts |
| Scleroderma Experts: EUSTAR and SCTC Worldwide Listings. Scleroderma is a rare disease so it is best to consult an expert as soon as possible to be assured of the latest treatment information, and for the opportunity to enroll in clinical trials. |
|
|
U.S. Morphea Registry and DNA Repository |
| First U.S. Morphea Registry and DNA Repository for both Adults and Children Established. Dermatologists at University of Texas Southwestern Medical Center are establishing a DNA repository aimed at people with morphea. They will collect information about other health conditions present, collect information about family history, and collect blood and skin samples to further define the genes associated with morphea and the genetic faces of morphea. Southwestern Medical Center. 05/31/07. (Also see: What is Morphea?) |
Pulmonary Hypertension Registry of Scleroderma by SCTC |
 Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): Two-Year Outcomes for Patients with Pulmonary Hypertension (PH). All PH groups had very low DLCOs, 31% of SSc patients with mPAP>25mmHg did not have PAH. PAH patients had higher mPAP and more anticentromere patients. PHA Online University, 2010. |
| Pulmonary Hypertension Registry of Scleroderma (PHAROS) is a multicenter study of systemic scleroderma (systemic sclerosis) patients in the United States who are at high risk for developing pulmonary hypertension as well as those with newly diagnosed with pulmonary hypertension, by members of the Scleroderma Clinical Trial Consortium (SCTC). Posted 04-10-06. ISN. |
Twins and Siblings With and Without Autoimmune Diseases |
| Still enrolling as of 10/15/12. |
 Families with Twins or Siblings where one has Systemic Rheumatic Disorders (Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis, Lupus, Scleroderma, or Myositis) and one does not. The goal of study 03-E-0099 is to assess why one twin or sibling developed disease and why the other brother or sister did not.
The siblings may or may not be twins, but must be of the same gender and be within a 3-year age difference. Biological parents, or, in some cases, children, will also be included in the study.
Families may enroll at the NIH Clinical Center in Bethesda, Maryland, just 9 miles north of Washington, DC or at their local physician's office. Transportation assistance may be available and there is no charge for study-related evaluations and medical tests.
For information on the study, call the NIH patient recruiting office toll free at 1-800-411-1222 (For TTY: 1-866-411-1010). National Institutes of Health Clinical Center (NIH). 11/25/05. (Also see: Scleroderma Research Registries and Causes of Scleroderma: Genetics) |
U.K. Registries for Systemic Sclerosis (Scleroderma) Patients |
| United Kingdom: Research Registry for UK Systemic Sclerosis Patients (Royal Free Hospital). Researchers and Pharmaceutical organizations with projects and trials under consideration are also welcome to contact us. |
| |
U.S. and Canada Scleroderma Registries |
| NIAMS Funds New Centers of Research Translation. One of the new centers is the Center for Research Translation in Scleroderma to study the molecular basis of scleroderma to understand its underlying causes using functional genomics and gene networks. Studies will involve a multiethnic cohort of scleroderma patients, as well as two mouse models of fibrosis recently developed at this center. Center will be headed by Frank Arnett, M.D. NIH News. 11/08/06. |
| Scleroderma Family Registry and DNA Repository Patients in the United States and Canada area are encouraged to register. This registry will help to identify clusters in certain areas or families, track the prevalence of scleroderma, and serve as a resource for scleroderma researchers. Enrollees may also be contacted to participate in clinical trials. |
|
|